1. Home
  2. ALT vs RLMD Comparison

ALT vs RLMD Comparison

Compare ALT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Altimmune Inc.

ALT

Altimmune Inc.

N/A

Current Price

$1.45

Market Cap

377.4M

Sector

Health Care

ML Signal

N/A

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

N/A

Current Price

$2.95

Market Cap

348.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALT
RLMD
Founded
1997
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
377.4M
348.8M
IPO Year
2005
2012

Fundamental Metrics

Financial Performance
Metric
ALT
RLMD
Price
$1.45
$2.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
4
Target Price
★ $16.33
$10.75
AVG Volume (30 Days)
★ 3.8M
1.7M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
25.37
★ 45.28
EPS
N/A
★ N/A
Revenue
★ $41,000.00
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
105.00
★ 154.83
52 Week Low
$1.50
$2.98
52 Week High
$6.44
$8.00

Technical Indicators

Market Signals
Indicator
ALT
RLMD
Relative Strength Index (RSI) 21.10 36.14
Support Level N/A N/A
Resistance Level $3.35 $4.74
Average True Range (ATR) 0.14 0.43
MACD -0.03 -0.09
Stochastic Oscillator 1.26 4.62

Price Performance

Historical Comparison
ALT
RLMD

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: